NCT07043270View on ClinicalTrials.gov

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2029

Conditions
Pancreas Adenocarcinoma
Interventions
DRUG

Nab-paclitaxel + Gemcitabine

Administered ion days 1, 8 and 15 of cycles 1 and 3 (28-day cycles).

DRUG

modified FOLFIRINOX (mFOLFIRINOX)

Administered ion days 1 and 15 of cycles 2 and 4 (28-day cycles).

Trial Locations (1)

03756

RECRUITING

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT07043270 - 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC | Biotech Hunter | Biotech Hunter